hereditary hemochromatosis of six patients who presented with iron overload but were simple heterozygotes for HFE C282Y mutation at first genetic testing. Functional impairment of new variants was deduced from computational methods including molecular modeling studies.
Results. We identified four rare HFE mutant alleles, three of which are undescribed. One mutation is a 13 nucleotide deletion in exon 6 (c.1022_1034del13, p.His341_Ala345>LeufsX119), which is predicted to lead to an elongated and unstable protein.
The second one is a substitution of the last nucleotide of exon 2 (c.340G>A, p.Glu114Lys) that modifies the relative solvent accessibility in a loop interface. The third, p.Arg67Cys, lies also in exon 2 and introduces a destabilization of the secondary structure within a loop of the α 1 domain. We also found the previously reported c.548T>C (p.Leu183Pro) missense mutation in exon 3. No other known iron genes were mutated. We present an algorithm at the clinical and genetic levels for identifying patients deserving further investigation.
Conclusions.
Our results suggest that additional mutations in HFE may have a clinical impact in C282Y carriers. In conjunction with previously described cases we conclude that elevated transferrin saturation level and elevated hepatic iron index should indicate searching for further HFE mutations in C282Y heterozygotes prior to other iron gene studies.
Introduction
Genetic Hemochromatosis (GH) is one of the most frequent genetics disorders in the Caucasian population. The clinical picture is that of multisystemic disease. Progressive accumulation and deposition of iron in parenchymal cells can lead to hepatic cirrhosis, diabetes, cardiomyopathy and other complications. Two mutations were initially described within the hemochromatosis gene (HFE), namely the p.Cys282Tyr (C282Y) and the p.His63Asp (H63D) mutations (1) .
Homozygosity for the C282Y mutation is the most frequent genotype associated with the common adult form of GH. C282Y carriers do not usually develop iron overload. The potential role of acquired factors, such as excess alcohol intake, diabetes and liver diseases has been proposed to explain the occurrence of iron overload in those heterozygotes displaying iron overload, although it is controversial (2-4). On the other hand, an associated genetic defect can be involved. Among these, the more frequent is the compound heterozygous state for C282Y
and the widespread p.His63Asp (H63D) variant allele (1, 5, 6) . Overall compound C282Y/H63D heterozygosity has been reported to account for 2-5% of cases of GH with a phenotypic expression in published series (7) (8) (9) . More rarely, compound heterozygotes for C282Y and the p.Ser65Cys (S65C) allele have been found to display very mild iron overload (10) .
Depending on the population studied, 1.5 to 16.4 % of patients presenting with the hemochromatosis phenotype carry only a unique C282Y allele (7, (11) (12) (13) (14) (15) .
Hemochromatosis in such patients suggests genetic and/or allelic heterogeneity. Indeed, rare alleles have been reported, the majority inherited in trans with the C282Y mutation (16) . These rare mutants are referred to as private mutations because they are found occasionally in a small number of individuals usually belonging to the same kindred. In routine clinical practice, the question is how to reach such a diagnosis when subjects with elevated iron indices are simple heterozygotes for the C282Y mutation at first genetic testing and how to decide if additional genetic studies are required. We describe new HFE mutations identified during the investigation of patients with C282Y heterozygosity and iron overload. We propose a diagnostic strategy to detect rare HFE variants at the light of hereafter and previously described cases.
Design and Methods
We investigated six C282Y carrier patients from 4 unrelated French families with high iron and S65C mutations was performed using PCR-RFLP (6) . DNA sequencing of the exons, exon-intron boundaries and the 5'untranslated region of HFE, HAMP, HJV/HFE2, TFR2 and SLC40A1 genes was undertaken as previously described (19, 20) . When a new HFE mutant was identified, it was systematically confirmed on a second sample using a sequencing approach or PCR-RFLP if a restriction site was altered by the mutation. Its absence was verified on a sample of 100 unrelated chromosomes of controls without iron overload. Guruprasad et al. (21) . For other variants, molecular modeling was performed using the AMBER 6.0 package as previously described (12) . The coordinates of HFE were taken from the 2.6 Angstrom crystal structure (22) and were used as starting geometry for both wild type and mutant proteins, while the interactions of the α1-α2 domains with TfR1 were obtained from the 1 DE4 PDB structure (23) . Molecular visualization was achieved using the VMD program (24) .
Results
We identified four rare HFE mutant alleles in six patients (Table 1) , three of which have not been previously reported. The probands' age ranged from 26 to 42 years and SF levels from 345 to 3250 µg/L. Liver iron content was measured in 4 out of six subjects and HII was found to be higher than 2 µmol/g/year in all of them.
Patient M1 was 37 years old at diagnosis and had very high SF levels (3250 µ g/L) with elevated TS (62%). Liver iron was not measured at that time, but he underwent regular phlebotomies during 15 years, with a total of 38 during the first 2 years to normalize ferritin levels. This corresponds to an initial removal of about 7.6 g iron. In addition to HFE C282Y, Two brothers, M2 and M3, aged 40 and 42 years respectively at diagnosis, were referred and diagnosed independently. Serum ferritin levels were mildly increased (483 and 397µg/L, respectively) and TS was > 60%. HII (as determined by MRI) was 4.8 µmol/g/year in the older and 5.5 µmol/g/year in the younger brother. Phlebotomies were undertaken for both of them.
Both brothers were found to be heterozygous for a substitution of the last nucleotide in exon 2 (c.340G>A, p.Glu114Lys). This mutation is located within a loop (110-114: HSKE) between helix 102-109 and strand 116-125. The loss of a negative charge dramatically increases the pI (pI is 6.36 for the variant versus 6.12 for the wild type) and shows a modification in the relative solvent accessibility at the loop interface.
Patients A1 and A2, were also brothers, aged 36 and 26 years respectively at diagnosis. Despite the fact that dysmetabolic syndrome has been reported to reduce the amount of iron overload in HH patients (25) , patient A1, who possibly had an associated dysmetabolic syndrome had higher iron parameters (SF = 952 µg/L and TS = 80%) when compared to his brother (SF = 345 µg/L and TS = 65%) with no associated dysmetabolic syndrome. Patient A1 underwent phlebotomies with a total of 2.5 g iron removed to decrease ferritin levels down to 50 µg/L.
The presence of high TS levels in both brothers and the family history were the reason for referral for genetic analysis. Both brothers had a single copy of HFE exon 2 missense mutation, p.Arg67Cys, in trans to HFE C282Y. The p.Arg67Cys mutation leads to a loss of positive charge (pI is 6.01 for the variant versus 6.12 for the wild type) which introduces a loss of flexibility of the 61-69 loop in the alpha-1 domain of the protein, resulting in destabilization of the secondary structure in this part of the molecule.
Lastly, patient B1, the only female in this series, was 28 years of age at diagnosis with high SF (645 µ g/L) and TS (80%) and a HII of 7.7 µ mol/g/year as measured by MRI. Phlebotomy therapy was undertaken and was well tolerated. This woman was found to be a compound heterozygote for a previously described c.548T>C (p.Leu183Pro) missense mutation in exon 3
of HFE and C282Y (26) .
No mutation was found in the HAMP, HJV(HFE2), TFR2 and SLC40A1 genes of all the six patients.
Literature screening (1999 to 2010) retrieved 15 previously described families (20 probands) with compound heterozygosity for C282Y and another private HFE mutation (Table 2 ).
Among the previously described patients, there were only 3 females (sex ratio M/F: 5. 
Discussion
In the present study we report six new cases of hemochromatosis from four unrelated families who were compound heterozygotes for the HFE C282Y mutation and a private HFE mutation in trans. Three of these genotypes have not been previously described and are due to three novel allelic variants. One (p.His341_Ala345>LeufsX119) is a frameshift mutation resulting from a 13 base pair deletion in exon 6, while the 3 others (p.Arg67Cys, p.Glu114Lys, p.Leu183Pro) are missense mutations.
The only female patient in this series bore a mutation (p.Leu183Pro) previously described in two unrelated Dutch probands (26) in trans with C282Y. Bioinformatics analysis of the p.Leu183Pro mutant showed that this mutation is likely to disturb the interaction between the HFE protein and transferrin receptor 1 (TfR1) (26) . A founder effect has been suggested on the basis of haplotype analysis of this mutation, however we do not know if the French proband had Dutch ancestors. Our female patient was 28 year-old when she was diagnosed with marked iron overload (HII: 7.7 µmol/g/year).
It should be noted that 17 out of 20 (85%) compound heterozygotes for C282Y and another HFE allelic variant (excluding the C282Y/H63D genotype), reported in the literature are males.
This might indicate that the clinical expression is milder or absent in females as it is also the case in C282Y homozygotes (27) (28) (29) . Including the cases here, a total of 18 private HFE mutations have been described in a compound heterozygous state with C282Y. Analysis of the available reports (Tables 1 and 2) shows that the majority of private mutations are located in exon 2 (8 cases), five mutations are located in exon 3, and three mutations have been found in exon 4. One mutation only lies in a splice junction (IVS3+1G>T) (figure 1). We also report here, to the best of our knowledge, the first ever described mutant in HFE exon 6 (c.1022_1034del13) introducing a frameshift mutation (p.His341_Ala345>LeufsX119). This mutation results in a new protein with a C-terminal extension of 119 amino acids with a stop codon in position 459. The prediction of the (p.His341_Ala345>LeufsX119) variant structure could not be built with precision using the molecular dynamics technology. An alternative was using homology modeling programs but none of them is accurate enough to deliver solid results (too many potential structures have been proposed).
The p.Arg67Cys substitution lies in the vicinity of the H63 and S65 residues. The R67 residue is inserted within a loop: ESRR (mutated for ESRC) which is well conserved in different species. It has been shown that mutants H63D and S65C bind TfR with affinities similar to that of wild-type HFE (30) . Using molecular modeling we confirm that Arg67 makes no direct contacts at the HFE-TfR interactions. Nevertheless, as already described for the p.Arg66Cys substitution (15) the p.Arg67Cys mutation might have functional relevance due to the destabilization of the 61-69 loop.
It is noteworthy that 17 out of 18 private HFE mutations described so far in conjunction with C282Y (including those presented here) are highly deleterious: 12 of the 18 (67%) are null mutations including nonsense, frameshift or mutants pertaining to consensus splice sites and at least 5 are missense mutations occurring at critical residues involved in HFE-TfR1 binding (23) at positions 43, 93, 168 and 183 (11, 26, 31, 32) of the protein sequence or leading to a complete destabilizing effect on the tertiary structure of the HFE protein (p.Q283P) (12) ( Tables 1 and 2 ). This may explain why the resulting phenotype is as, or more, severe than the phenotype of C282Y homozygotes among the affected patients. It is also worth noting that the mean age at diagnosis is relatively younger in our patient group when compared to those reported in literature ( In a fourth step, HFE sequencing can be undertaken and may identify new HFE variants as described here.
It should be noticed that high TS level is a particularly valuable indicator for the presence of a HFE mutation and that patients with uncommon compound genotypes have TS significantly higher than the usual cut-off for GH (i.e. usually > 45%) (34, 35) . Indeed, we calculated a mean TS of 88.3 + 10.0 % from 20 published cases (shown in table 2 A and B), and 84.5 + 12.3% when including the 6 patients described in this study. These results confirm that the findings of high TS in such patients together with elevated hepatic iron amounts are important indicators for first searching for further HFE mutation in C282Y heterozygotes prior to other iron related gene investigation. This also explains our choice of high TS threshold (60% in adult males and 50% in adult females) as inclusion criteria (see design and methods and table 3) rather than common threshold of > 45%. These thresholds have already been used in similar circumstances for the detection of HFE compound heterozygotes (12) . In our experience using lower TS threshold leads to many unnecessary genetic analyses. It is worthy to note that recent publications on screening for HFE C282Y homozygotes also used cut-off for TS higher than 45% : > 50% in men (36) or > 50% in women and > 55% in men (37) .
In a recently published series it has been calculated that 33% of p.Cys282Tyr heterozygous patients affected with significant iron overload, had a rare mutation in HFE (35) . Detecting these new mutants has both biological and clinical implications: insight on the functional domains of the HFE protein and management of iron overload in the probands including family screening and genetic counseling among relatives.
Lastly, patients who have no additional HFE mutant alleles, will deserve further investigation of other genes implicated in iron overload in order to search for digenism or multigenism (38) .
This will include analysis of HAMP, HJV, TFR2 and SLC40A1. However in clinical practice, once hepatic iron overload has been proven, phlebotomies must be undertaken rapidly without waiting for sequencing result. Quantization of total iron removed by phlebotomies may serve as an additional argument to evaluate retrospectively the extent of iron accumulation.
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The authors reported no potential conflicts of interest. Step strategy for the diagnosis of rare HFE mutations associated with C282Y in a compound heterozygous state
Step Action undertaken
Step 1
Basic biology and clinical examination
• Hyperferritinemia in an adult (M > 300 µg/L, F> 200 µg/L)
• High TS (M> 60%, F> 50%)
• Exclude acquired causes: Hematological disorder, Alcohol, Cell necrosis.
Step 2
Basic genetic testing
• Test HFE (C282Y)
• C282Y homozygote: HFE hemochromatosis : stop (unless very severe iron overload, follow step 4-2)
• C282Y heterozygote • Other HFE genotypes: follow step 3
Step 3 Quantification of hepatic iron (MRI or liver biopsy*)
1. HII< 1.9 µmol/g/year (17): stop 2. HII> 1.9 µmol/g/year: follow step 4
Step 4
Specialized genetic testing
 Sequence the HFE gene:
1. Presence of a private HFE mutation (can explain iron overload) 
